Who is sponsoring NCT05273528?

NCT05273528 is sponsored by Livzon Pharmaceutical Group Inc..

What condition does NCT05273528 study?

NCT05273528 studies COVID-19 Pandemic.

Is NCT05273528 still recruiting?

NCT05273528 is currently status unknown. Last updated 10 March 2022.

Last reviewed 2022-03-10 · How we verify

NCT05273528: Omicron

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Immunogenicity and Safety of V-01-351/V-01D Bivalence Vaccine

Status unknown Phase 2 Last updated 10 March 2022

What this trial tests

Phase 2 trial testing Recombinant SARS-CoV-2 Beta Variant Fusion Protein Vaccine/Recombinant SARS-CoV-2 Delta Variant Fusion Protein Vaccine in COVID-19 Pandemic in 20 participants. Status unknown.

Timeline

11 January 2022

Primary endpoint
6 January 2023

6 January 2023

Quick facts

Lead sponsor	Livzon Pharmaceutical Group Inc.
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	20
Start date	11 January 2022
Primary completion	6 January 2023
Estimated completion	6 January 2023
Sites	1 location across China

Drugs / interventions tested

Recombinant SARS-CoV-2 Beta Variant Fusion Protein Vaccine/Recombinant SARS-CoV-2 Delta Variant Fusion Protein Vaccine

Conditions studied

COVID-19 Pandemic — all drugs for COVID-19 Pandemic →

Sponsor

Livzon Pharmaceutical Group Inc. — full company profile →

Who can join

18 and older, any sex, with COVID-19 Pandemic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

It is a Single Arm, Open Label Clinical Study to Evaluate the Immunogenicity and Safety of Sequential Immunization of V-01-351/V-01D Bivalence Vaccine in Healthy Adults Aged 18 Years and Older After the Vaccination of 2 Doses of Inactivated Vaccines. A total of 20 participants were enrolled.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Challenges and developments in universal vaccine design against SARS-CoV-2 variants.
Zhao F, Zai X, Zhang Z, Xu J, et al · · 2022 · cited 55× · PMID 36535982 · DOI 10.1038/s41541-022-00597-4
A Heterologous V-01 or Variant-Matched Bivalent V-01D-351 Booster following Primary Series of Inactivated Vaccine Enhances the Neutralizing Capacity against SARS-CoV-2 Delta and Omicron Strains.
Zhang Z, He Q, Zhao W, Li Y, et al · · 2022 · cited 18× · PMID 35887928 · DOI 10.3390/jcm11144164

Verify or expand the search:

Other recruiting trials for COVID-19 Pandemic

Currently open trials in the same condition.

NCT05825651 — Long COVID and Its Associations With Health Outcomes in Older Adults · active not recruiting
NCT06927622 — Corona Virus Disease 2019 Cohort Study · recruiting
NCT05096260 — Getting to Yes, Michigan! (G2YMI) · NA · active not recruiting
NCT06208943 — Neural and Cognitive Consequences of COVID-19 Survival · recruiting

Other Livzon Pharmaceutical Group Inc. trials

Trials by the same sponsor.

NCT06963320 — Phase II Clinical Study of H001 Capsule in the Prevention of Venous Thromboembolism After Total Knee Arthroplasty · Phase 2 · recruiting
NCT06850480 — A Phase III Clinical Trial for Efficacy and Safety Evaluation of JP-1366 Tablets on Reflux Esophagitis · Phase 3 · recruiting
NCT05585567 — A Preliminary Exploratory Study to Evaluate the Safety and Immunogenicity of Omicron Variant Bivalent Vaccine V-01-B5 · EARLY_PHASE1 · unknown
NCT05583357 — Exploratory Clinical Study to Evaluation of the Safety and Immunogenicity of Bivalent Vaccine V-01D-351 · EARLY_PHASE1 · unknown
NCT05238649 — Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine · Phase 2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05273528 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Livzon Pharmaceutical Group Inc.
Last refreshed: 10 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05273528.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing